Research Library

This study finds that Maryland's all-payer model for healthcare comparatively lowered the risk of complications from surgery, as well as reducing increases in associated costs.

This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.

Hospital at Home programs offer an alternative care model for acutely ill patients to receive intensive at-home treatment. With better policy and operations, can this model work at scale in the United States beyond the pandemic?

Vaginitis is one of the most common reasons women access health care in the United States. Despite its prevalence and disruptive impact, it is frequently misdiagnosed and untreated, resulting in unnecessary patient discomfort, follow-up visits, and health care costs.

The unproven stem cell intervention industry is a worldwide, direct-to-consumer market where clinics offer stem cells or stem cell-derived components to patients with little to no scientific or clinical basis. In this paper, the authors call for the establishment of a World Health Organization Expert Advisory Committee on Regenerative Medicine to tackle this issue and provide guidance. Stem Cell Reports: https://doi.org/10.1016/j.stemcr.2021.05.004

Private equity investment in hospitals has grown substantially in the 21st century, and it accelerated in the years leading up the COVID-19 pandemic. In this study of short-term acute care hospitals acquired by private equity firms, the authors find they not only have higher markups and profit margins, they’re also slower to expand their staffs.

The authors sought to develop and test a tool that accurately predicts the unique financial burden to individual patients undergoing treatment for breast cancer. JCO Clinical Cancer Informatics, an American Society of Clinical Oncology Journal

Vaccines and other biomedical advances will not be sufficient to halt COVID-19, unless we simultaneously counter anti-science aggression, writes Peter Hotez, fellow in disease and poverty, in a new article for PLOS Biology.

It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it, write the authors.